MX344725B - Metodo entrelazado para tratar cancer o una condicion precancerosa. - Google Patents
Metodo entrelazado para tratar cancer o una condicion precancerosa.Info
- Publication number
- MX344725B MX344725B MX2011012940A MX2011012940A MX344725B MX 344725 B MX344725 B MX 344725B MX 2011012940 A MX2011012940 A MX 2011012940A MX 2011012940 A MX2011012940 A MX 2011012940A MX 344725 B MX344725 B MX 344725B
- Authority
- MX
- Mexico
- Prior art keywords
- eukaryotic cells
- calcium channel
- dosage
- type calcium
- channel inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 208000006994 Precancerous Conditions Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- DKNDOKIVCXTFHJ-HNNXBMFYSA-N 3,5-dichloro-n-[[1-[[(4s)-2,2-dimethyloxan-4-yl]methyl]-4-fluoropiperidin-4-yl]methyl]benzamide Chemical compound C1COC(C)(C)C[C@H]1CN1CCC(F)(CNC(=O)C=2C=C(Cl)C=C(Cl)C=2)CC1 DKNDOKIVCXTFHJ-HNNXBMFYSA-N 0.000 abstract 3
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 3
- 230000010190 G1 phase Effects 0.000 abstract 2
- 230000022131 cell cycle Effects 0.000 abstract 2
- 230000010337 G2 phase Effects 0.000 abstract 1
- 230000027311 M phase Effects 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000018199 S phase Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002250 progressing effect Effects 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18465809P | 2009-06-05 | 2009-06-05 | |
| PCT/US2010/037437 WO2010141842A2 (en) | 2009-06-05 | 2010-06-04 | Interlaced method for treating cancer or a precancerous condition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011012940A MX2011012940A (es) | 2012-04-20 |
| MX344725B true MX344725B (es) | 2017-01-05 |
Family
ID=43298556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011012940A MX344725B (es) | 2009-06-05 | 2010-06-04 | Metodo entrelazado para tratar cancer o una condicion precancerosa. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120088807A1 (enExample) |
| EP (1) | EP2437749B8 (enExample) |
| JP (2) | JP5806210B2 (enExample) |
| KR (2) | KR20120030112A (enExample) |
| CN (2) | CN106177963A (enExample) |
| AU (1) | AU2010256442B2 (enExample) |
| CA (1) | CA2764499A1 (enExample) |
| DK (1) | DK2437749T3 (enExample) |
| ES (1) | ES2661216T3 (enExample) |
| IL (2) | IL216443A (enExample) |
| MX (1) | MX344725B (enExample) |
| PL (1) | PL2437749T3 (enExample) |
| SG (3) | SG176678A1 (enExample) |
| WO (1) | WO2010141842A2 (enExample) |
| ZA (1) | ZA201108909B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102781316B (zh) | 2010-03-01 | 2016-07-06 | 陶制药有限责任公司 | 癌症诊断和成像 |
| EP2755674A4 (en) * | 2011-09-12 | 2015-04-08 | Tau Therapeutics Llc | ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS |
| US11642353B2 (en) | 2014-02-06 | 2023-05-09 | The Procter & Gamble Company | Hair care composition comprising antidandruff agent and polyquaternium-6 |
| US11058624B2 (en) | 2014-02-06 | 2021-07-13 | The Procter And Gamble Company | Hair care composition comprising cationic polymers and anionic particulates |
| EP3364993B1 (en) | 2015-10-22 | 2022-11-09 | Cavion, Inc. | Methods for treating angelman syndrome |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN110545806A (zh) | 2017-02-15 | 2019-12-06 | 卡维昂公司 | 钙通道抑制剂 |
| EP3615521A4 (en) | 2017-04-26 | 2021-02-17 | Cavion, Inc. | METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS |
| JP7480131B2 (ja) | 2018-10-03 | 2024-05-09 | カビオン・インコーポレイテッド | （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 |
| CN118217178A (zh) | 2018-10-04 | 2024-06-21 | 宝洁公司 | 包含水不溶性固体有机化合物的个人护理组合物 |
| BR112021013766A2 (pt) | 2019-03-01 | 2021-09-21 | Flamel Ireland Limited | Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251886B1 (en) * | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
| US7985422B2 (en) * | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US20060003020A1 (en) * | 2004-03-11 | 2006-01-05 | The Regents Of The University Of Michigan | Anti-metastatic ability of mibefradil and gadolinium |
| TW200538149A (en) * | 2004-05-20 | 2005-12-01 | Telik Inc | Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound |
| US20060000320A1 (en) * | 2004-06-30 | 2006-01-05 | Hutton William M | Ratchet wrench tool assembly for underground work and process of using |
| CA2576186A1 (en) * | 2004-08-20 | 2006-03-02 | University Of Virginia Patent Foundation | T type calcium channel blockers and the treatment of diseases |
| CA2576191C (en) * | 2004-08-20 | 2013-03-19 | University Of Virginia Patent Foundation | T type calcium channel inhibitors |
| CN100546579C (zh) * | 2006-12-30 | 2009-10-07 | 南京工业大学 | 替莫唑胺聚乳酸纳米微球与制剂及其制备方法 |
| WO2008141189A1 (en) * | 2007-05-09 | 2008-11-20 | Elixir Pharmaceuticals, Inc. | Ghrelin modulating compounds and combinations thereof |
-
2010
- 2010-06-04 KR KR1020117031182A patent/KR20120030112A/ko not_active Ceased
- 2010-06-04 CN CN201610829079.8A patent/CN106177963A/zh active Pending
- 2010-06-04 KR KR1020177022797A patent/KR101905050B1/ko not_active Expired - Fee Related
- 2010-06-04 PL PL10784166T patent/PL2437749T3/pl unknown
- 2010-06-04 SG SG2011089885A patent/SG176678A1/en unknown
- 2010-06-04 SG SG10201810806UA patent/SG10201810806UA/en unknown
- 2010-06-04 DK DK10784166.0T patent/DK2437749T3/da active
- 2010-06-04 CN CN2010800247574A patent/CN102458416A/zh active Pending
- 2010-06-04 ES ES10784166.0T patent/ES2661216T3/es active Active
- 2010-06-04 WO PCT/US2010/037437 patent/WO2010141842A2/en not_active Ceased
- 2010-06-04 MX MX2011012940A patent/MX344725B/es active IP Right Grant
- 2010-06-04 CA CA2764499A patent/CA2764499A1/en not_active Abandoned
- 2010-06-04 SG SG10201402863PA patent/SG10201402863PA/en unknown
- 2010-06-04 EP EP10784166.0A patent/EP2437749B8/en not_active Not-in-force
- 2010-06-04 US US13/375,846 patent/US20120088807A1/en not_active Abandoned
- 2010-06-04 JP JP2012514182A patent/JP5806210B2/ja not_active Expired - Fee Related
- 2010-06-04 AU AU2010256442A patent/AU2010256442B2/en not_active Ceased
-
2011
- 2011-11-17 IL IL216443A patent/IL216443A/en active IP Right Grant
- 2011-12-05 ZA ZA2011/08909A patent/ZA201108909B/en unknown
-
2015
- 2015-09-03 JP JP2015173818A patent/JP6159958B2/ja not_active Expired - Fee Related
-
2016
- 2016-10-25 IL IL248482A patent/IL248482B/en not_active IP Right Cessation
-
2018
- 2018-01-12 US US15/870,355 patent/US20180228822A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP5806210B2 (ja) | 2015-11-10 |
| SG10201402863PA (en) | 2014-10-30 |
| WO2010141842A2 (en) | 2010-12-09 |
| PL2437749T3 (pl) | 2018-04-30 |
| SG176678A1 (en) | 2012-01-30 |
| CN106177963A (zh) | 2016-12-07 |
| DK2437749T3 (da) | 2018-01-29 |
| ES2661216T3 (es) | 2018-03-28 |
| EP2437749A2 (en) | 2012-04-11 |
| EP2437749B8 (en) | 2018-02-21 |
| IL216443A (en) | 2016-11-30 |
| CN102458416A (zh) | 2012-05-16 |
| EP2437749B1 (en) | 2017-12-20 |
| KR20120030112A (ko) | 2012-03-27 |
| WO2010141842A3 (en) | 2011-04-21 |
| US20120088807A1 (en) | 2012-04-12 |
| JP2016028058A (ja) | 2016-02-25 |
| KR101905050B1 (ko) | 2018-10-08 |
| SG10201810806UA (en) | 2019-01-30 |
| MX2011012940A (es) | 2012-04-20 |
| EP2437749A4 (en) | 2013-04-17 |
| IL248482A0 (en) | 2016-12-29 |
| JP6159958B2 (ja) | 2017-07-12 |
| US20180228822A1 (en) | 2018-08-16 |
| ZA201108909B (en) | 2013-02-27 |
| JP2012528890A (ja) | 2012-11-15 |
| AU2010256442A1 (en) | 2012-01-19 |
| KR20170097237A (ko) | 2017-08-25 |
| CA2764499A1 (en) | 2010-12-09 |
| AU2010256442B2 (en) | 2016-07-21 |
| IL216443A0 (en) | 2012-02-29 |
| IL248482B (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011012940A (es) | Metodo entrelazado para tratar cancer o una condicion precancerosa. | |
| WO2012092458A3 (en) | Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof | |
| TN2011000414A1 (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitors, and uses thereof | |
| PA8778101A1 (es) | Metodos y composiciones para tratar y monitorear el tratamiento de trastornos asociados con il-13 | |
| MX2011008340A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente. | |
| MX381987B (es) | El uso de un agente inhibidor de masp-2 para tratar condiciones asociadas con la activacion del complemento dependiente de masp-2 | |
| UA106634C2 (uk) | Тверда фармацевтична дозована форма | |
| MY158504A (en) | Fatty acid niacin conjugates and their uses | |
| EP4285988A3 (en) | Treating fibrosis by inhibiting tl1a | |
| UA103614C2 (uk) | Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки | |
| EA200802324A1 (ru) | Новая форма введения рацекадотрила | |
| PH12014500075A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| WO2011109262A3 (en) | Cancer diagnosis and imaging | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad | |
| PH12012501389A1 (en) | Hedgehog inhibitors | |
| CY1121973T1 (el) | Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα | |
| GB2496795A (en) | A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system | |
| WO2010117727A3 (en) | Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions | |
| CA2866819C (en) | Method for treating inflammation | |
| IN2014DN09437A (enExample) | ||
| MX366309B (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| MX2010013790A (es) | Composiciones y metodos para tratar inflamacion de corneas. | |
| MX2014003093A (es) | Combinacion de pterostilbeno y estatina para el tratamiento de enfermedad metabolica, enfermedad cardiovascular e inflamacion. | |
| PH12015502560A1 (en) | Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease | |
| CL2010001230A1 (es) | Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |